Kyowa Kirin Responds to NICE’s Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1
Kyowa Kirin regrets the National Institute for Health and Care Excellence’s (NICE) negative interim decision but remains committed to working…